Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate - LOLA)
## Overview
LOLA is a stable salt of two amino acids (ornithine and aspartate) used to facilitate the detoxification of ammonia in the urea cycle and glutamine synthesis pathway. It is primarily used to manage hyperammonemia in liver disease.
## Primary Indications
* Treatment of hyperammonemia in acute and chronic liver disease (e.g., liver cirrhosis, hepatitis).
* Adjunctive therapy for hepatic encephalopathy (HE).
## Adult Dosing
* **Oral (Granules):** 3 g three times daily, taken with or after meals dissolved in a glass of water.
* **Intravenous (Ampoules):** 5 g to 10 g daily by slow infusion. In cases of pre-coma or coma, up to 20 g daily may be infused depending on clinical severity.
* **IV Infusion Rate:** Do not exceed 5 g per hour to prevent nausea and vomiting.
## Pediatric Dosing
* **Data remains limited.** Dosage is generally extrapolated, often calculated at 100–200 mg/kg/day, but pediatric use should be strictly restricted to specialist hepatology guidance.
## Dose Adjustments
* **Renal Impairment:** Reduce dose or avoid in patients with severe renal insufficiency (serum creatinine > 3 mg/dL or > 265 µmol/L), as the aspartate component can accumulate.
* **Hepatic Impairment:** No dose reduction required for liver failure, as this is the target indication.
## Contraindications
* Severe renal insufficiency (creatinine > 3 mg/dL).
* Known hypersensitivity to L-ornithine or L-aspartate.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence.
* **Rare:** Cough, muscle pain, limb pain, anaphylactic reactions (with rapid IV administration).
## Key Drug Interactions
* Minimal documented pharmacokinetic drug-drug interactions.
* Caution should be used when co-administering with other CNS depressants if treating severe hepatic encephalopathy, as the sedative effects of the underlying condition may mask therapeutic response.
## Monitoring
* Monitor serum ammonia levels (if available) to assess efficacy.
* Monitor renal function (BUN/Creatinine) regularly during therapy.
* Serial neurological assessments (e.g., West Haven Criteria) to monitor clinical status in patients with hepatic encephalopathy.
## Clinical Pearls
* **IV Compatibility:** LOLA is generally compatible with standard glucose or saline infusions; however, avoid mixing with other drugs in the same infusion container unless compatibility is verified.
* **Lactose Status:** Oral granules may contain additives; verify inactive ingredients for patients with underlying metabolic sensitivities.
* **Not a monotherapy:** LOLA is an adjunct; it does not replace the gold standard of lactulose or rifaximin in the management of overt hepatic encephalopathy.
* **Infusion Safety:** If nausea/vomiting occurs during IV administration, stop the infusion, ensure the rate is below 5 g/hour, and resume slowly.
***
**Educational Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Dosing and safety protocols may vary by local practice, institutional formulary, and official manufacturer prescribing information. Always verify current prescribing information and clinical guidelines before administering medication.
